Last updated: February 28, 2026
What is the Excipient Profile of CYSTO-CONRAY II?
CYSTO-CONRAY II, a diagnostic radiographic contrast agent, contains iohexol, an iodine-based compound. The excipient components typically include:
- Carrier agents: Water for injection acts as the primary solvent.
- Stabilizers: Sodium chloride to maintain isotonicity.
- pH adjusters: Sodium bicarbonate or sodium hydroxide.
- Preservatives: Usually none, given intravenous use.
- Chelating agents or co-solvents: Polyethylene glycol or glycerol are not commonly used in standard formulations but may be included in specialized versions.
The formulation relies on the osmolality and viscosity affecting the contrast agent's safety and efficacy.
How Do Excipients Influence the Drug’s Performance?
Excipients in CYSTO-CONRAY II modulate:
- Viscosity: Polyethylene glycol or glycerol can be added to enhance stability and influence transit time.
- Osmolality: Sodium chloride sets isotonicity, reducing adverse reactions.
- pH stability: Sodium bicarbonate adjusts pH to minimize discomfort upon injection.
- Shelf life and stability: Preservative-free formulations are common for IV contrast, but excipients can be optimized to prolong stability.
Alterations in excipient profile impact safety, tolerability, and regulatory compliance.
What Are the Commercial Opportunities in Exipient Optimization?
1. Developing Reduced-Osmolality Formulations
Standard iohexol solutions are high-osmolality (~300 mOsm/kg). Reduced-osmolality versions (~600-800 mOsm/kg), achieved through modifications in excipients like lower salt concentrations or alternative osmotic regulators, show:
- Lower adverse event profiles.
- Increased patient tolerability.
Market size: The global contrast media market surpassed $4 billion in 2022, expected to grow at 4% annually (Data from MarketsandMarkets).
2. Formulation Innovation for Safety and Compatibility
Innovations include substituting traditional excipients with:
- Biocompatible polymers: To reduce viscosity and improve injection ease.
- Alternative pH buffers: To lower discomfort and allergic reactions.
Commercially, these innovations enhance product differentiation and support premium pricing.
3. Customization for Specific Patient Populations
Formulations can be tailored:
- For renal-impaired patients: Using excipients that reduce nephrotoxicity.
- Pediatric formulations: Lower concentrations and excipients reducing allergenic potential.
These niches command higher margins and provide opportunities for licensing or direct sales.
4. Supply Chain and Manufacturing Efficiency
Optimizing excipient use can reduce costs:
- Bulk procurement of excipients like sodium chloride or glycerol.
- Scaling manufacturing to meet regulatory standards.
Cost leadership becomes feasible with efficient excipient management.
5. Expanding Indication Scope
Modified formulations could open new indications, such as intra-articular or other localized imaging procedures, requiring different excipient compositions for optimal safety.
Regulatory Considerations and Market Entry
- Regulatory agencies (FDA, EMA) emphasize excipient safety, especially for intravenous products.
- Novel excipients or significant formulation changes require rigorous stability and safety studies.
- Patent opportunities exist in proprietary formulation techniques, especially for reduced-osmolality or pediatric versions.
Key Challenges
- Ensuring stability and compatibility of excipients with the active ingredient.
- Regulatory approval delays for new formulations.
- Cost implications of excipient modifications.
Summary Table
| Aspect |
Standard Version |
Reduced-Osmolality Version |
Pediatric/Specific Version |
Market Opportunity |
| Excipient Focus |
Sodium chloride, pH adjusters |
Lower salt, alternative buffers |
Lower concentration, non-allergenic excipients |
Niche markets, premium pricing |
| Market Drivers |
Tolerability, safety |
Safety, tolerability |
Safety, dosing flexibility |
Growing global contrast agent market |
| Regulatory Needs |
Established safety profile |
Additional stability data |
Pediatric safety data |
Intellectual property opportunities |
Key Takeaways
- Excipient optimization in CYSTO-CONRAY II centers on reducing osmolality, improving tolerability, and expanding indications.
- Innovations in formulation can provide significant commercial advantages, such as access to niche markets and licensing deals.
- Cost efficiencies and regulatory strategies are critical for successful market entry and sustained competitiveness.
FAQs
1. Can excipient modifications impact the safety profile of CYSTO-CONRAY II?
Yes. Changes to excipients affect biocompatibility, stability, and potential allergenicity, necessitating thorough safety assessments.
2. What excipients are most critical in reducing adverse reactions?
Salt concentration (for osmolality) and pH buffers directly influence osmotic balance and patient comfort.
3. Is there a market demand for low-osmolality contrast agents?
Yes. Lower-osmolality formulations have demonstrated reduced adverse events, making them preferable for high-risk patient groups.
4. How do regulatory policies influence excipient changes?
Regulatory agencies require evidence of safety and efficacy for any formulation modifications, including stability and compatibility data.
5. What opportunities exist for licensing innovative formulations?
Patent-protected formulations with unique excipient profiles can attract licensing partnerships, especially if they demonstrate clinical benefits or cost advantages.
References
- MarketsandMarkets. (2022). Contrast Media Market by Type, Application, and Region. [Report].
